COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT06372457 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

331

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertrophic Cardiomyopathy (HCM)

Interventions

DRUG: Approved Hypertrophic Cardiomyopathy drug treatments
DRUG: Mavacamten

Sponsor

Bristol-Myers Squibb